



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرو فيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Comparative study of topical latanoprost, tacrolimus and clobetasol propionate in combination with microneedling and narrow-band ultraviolet B in the treatment of non-segmental vitiligo

Thesis

*Submitted for the Partial Fulfillment of M.Sc Degree in
Dermatology, Venerology and Andrology*

By

Ashraf Mohamed Shareef

M.B.B.Ch. 6 October University

Under supervision of

Prof. Dr. Mostafa Mokhtar Kamel

*Professor of Dermatology, Venerology and Andrology
Faculty of Medicine, Ain Shams University*

Dr. Ahmed Abd Elfattah Afify

*Lecturer of Dermatology, Venerology and Andrology
Faculty of Medicine, Ain Shams University*

*Faculty of Medicine
Ain Shams University
Cairo
2021*

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سَبِّحْكَ لَا إِلَهَ إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the
Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and profound
gratitude to **Prof. Dr. Mostafa Mokhtar Kamel**,
Professor of Dermatology, Venerology and Andrology Faculty
of Medicine - Ain Shams University for his keen guidance,
kind supervision, valuable advice and continuous
encouragement, which made possible the completion of this
work.*

*I am also delighted to express my deepest gratitude
and thanks to **Dr. Ahmed Abd Elfattah Afify**,
Lecturer of Dermatology, Venereology and Andrology
Faculty of Medicine - Ain Shams University, for his kind
care, continuous supervision, valuable instructions,
constant help and great assistance throughout this work.*

*Thanks for all Staff Members of Dermatology,
Venereology and Andrology Department, Ain Shams
University for their support.*

Ashraf Mohamed

List of Contents

Title	Page No.
List of Abbreviations.....	i
List of Tables	iii
List of Figures	iv
Introduction	1
Aim of the Work.....	4
Review of Literature	
Vitiligo.....	5
Microneedling.....	39
Patients and Methods.....	44
Results	56
Discussion	76
Conclusions	85
Recommendations	86
Summary	87
References	89
Arabic Summary	—

List of Abbreviations

Abb.	Full term
AGEs	Advanced glycation end-products
AIDS	Acquired immunodeficiency syndrome
ANOVA	Analysis of Variance
CBT	Cognitive behavioral therapy
CD	Cluster of differentiation
CP	Clobetasol propionate
DAMPs	Damage-associated molecular patterns
DHICA	Dihydroxyindole-2-carboxylic acid
DPCP	Diphenylcyclopropenone
DR	Derma roller
EGF	Epidermal Growth Factor
ER:YAG	Erbium-YAG
FDA	Food and Drug Administration
H₂O₂	Hydrogen peroxide
HCY	Homocysteine
HLA	Human Leukocyte Antigen
ICAM-1	Intra cytoplasmic adhesion molecule 1
IFN	Interferon
IL	Interleukin
JK	Janus kinase
KP	Koebner's phenomenon
LMP	Low molecular weight polypeptide
LT	Latanoprost
MBEH	Mono-benzyl ether of hydroquinone
MCH	Major histocompatibility complex
MCH	Melanin concentrating hormone
MSH	Melanocyte-stimulating hormone
NALP1	NACHT-LRR-PYD-containing protein 1
NB-UVB	Narrowband ultraviolet B

List of Abbreviations Cont...

Abb.	Full term
NCES	Non-cultured epidermal cell suspension
NK	Natural killer
NSAIDs	Nonsteroidal anti-inflammatory drugs
NSV	Non segmental vitiligo
PGFα	Prostaglandin F
PUVA	Psoralen with ultraviolet A
ROS	Reactive oxygen species
SBEG	Suction blister epidermal grafting
SOD	Superoxide dismutase
STAT	Signal transducer and activator of transcription
SV	Segmental vitiligo
TCA	Triamcinolone acetonide
TCIs	Topical calcineurin inhibitors
TGF	Transforming Growth Factor
TH	T helper
TNF	Tumour necrosis factor
Tregs	Regulatory T cells
TRP1	Tyrosinase-related protein 1
Tyk2	Tyrosine kinase 2
UV	Ultraviolet
VACAG	Vitiligo analysis by computer-assisted grid
VASI	Vitiligo Area Scoring Index
VEGF	Vascular Endothelial Growth Factor
VESTA	Vitiligo extent score for a target area
VIDA	Vitiligo Disease Activity Score
XE-CI	Xenon-Chlorine

List of Tables

Table No.	Title	Page No.
Table (1):	Demographic data of patients.....	56
Table (2):	Characteristics of vitiligo lesions in included patients	57
Table (3):	Assessment of vitiligo activity in studied patients using VIDA score	57
Table (4):	Patient satisfaction with different treatment modalities	58
Table (5):	VESTA score comparison between different treatment modalities.....	59
Table (6):	Comparison between surface area before and after treatment in each group.....	60
Table (7):	Comparison between surface area reduction after 1 month and after 6 months in each treatment group	61
Table (8):	Comparison of mean values of surface area reduction with controls	62
Table (9):	Correlation of surface area reduction after treatment with patients' age, duration of lesions and stability of vitiligo lesions	63
Table (10):	Side effects reported with each treatment modality	64

List of Figures

Fig. No.	Title	Page No.
Figure (1):	The autoimmunity of vitiligo is driven by IFN-gamma-CXCL10 cytokine signaling pathway	15
Figure (2):	Proposed patho-mechanisms behind the convergence theory.....	20
Figure (3):	Clinical image of blue vitiligo showing depigmented patches with bluish hue on some of the patches over the neck area.....	22
Figure (4):	Segmental variant of vitiligo on the left upper forehead at baseline.....	23
Figure (5):	Typical nonsegmental vitiligo	24
Figure (6):	Treatment algorithm for vitiligo.....	38
Figure (7):	Medical dermaroller	42
Figure (8):	Derma-roller (ZGTS 0.5MM, China).....	47
Figure (9):	Latanoprost (0.005% solution, Xalatan Eipico).	47
Figure (10):	NB-UVB cabinet (Villingen-Schwenningen Deutschland).	48
Figure (11):	Tacrolimus (0.1% ointment, Talimus, Ajanta).	48
Figure (12):	Clobetasole propionate cream (GSK dermovate)	48
Figure (13):	Calculation of VESTA score.....	52
Figure (14):	Example of surface area calculation	53
Figure (15):	41 years old male patient, (duration of lesions =20 years).....	66
Figure (16):	31 years old female patient, (duration of lesions = 6 years).....	69

List of Figures Cont...

Fig. No.	Title	Page No.
Figure (17):	38 years old male patient, (duration of lesions =5 years).....	71
Figure (18):	20 years old female patient, (duration of lesions = 3 years).....	73
Figure (19):	27 years old male patient, (duration of lesions =2 years).....	75

INTRODUCTION

Vitiligo is a hypomelanotic autoimmune skin disease resulting from loss of functional melanocytes from the skin with a prevalence of 1–2%. The disease can affect individuals of any race or sex and manifests before the age of 20 years in approximately half of all cases (*Dwivedi et al., 2015*).

The cause of vitiligo is not fully understood. There are a few major hypotheses for the pathogenesis of vitiligo which include the genetic, neural, autoimmune, biochemical, and melanocytorrhagy theories (*Choi et al., 2014*).

Possible treatment options include topical corticosteroids, calcineurin inhibitors, vitamin D derivatives, phototherapy with ultraviolet A (UVA) and narrow band ultraviolet B (NB-UVB), photochemotherapy with psoralen plus UVA (PUVA) and psoralen with sunlight, surgical techniques and combinations of topical therapies and light treatment (*Whitton et al., 2016*).

Nonsegmental vitiligo is characterized by a bilateral and often symmetrical distribution of the white patches, an unpredictable course, a polymorphous aspect of the lesions, a significant association with autoimmune diseases and a frequent family history (*Benzekri and Gauthier, 2014*). Nonsegmental vitiligo is the most common form of the disease (accounting for 85 to 90% of cases overall) (*Taïeb and Picardo, 2009*).

Narrow band ultraviolet B is considered as a “golden standard” in vitiligo treatment with high repigmentation rate, which is further increased when combined with other therapeutic options (*Stanimirovic et al., 2016*). Narrow band ultraviolet B phototherapy represents a symbol of a specific UVB wave, 311 ± 2 nm (*Oiso et al., 2013*).

Latanoprost (LT) is a prostaglandin F₂alpha analogue that can induce skin pigmentation, a side effect discovered through its use in glaucoma therapy. It upregulates tyrosinase and promotes melanocyte proliferation (*Dillon et al., 2017*).

Tacrolimus is a macrolide antibiotic produced by *Streptomyces tsukubaensis* with strong T-specific, immunosuppressant activity. Indeed, topical tacrolimus downregulates proinflammatory cytokines, namely IL-2, IL-3, IL-4, IL-5, IFN- γ , TNF- α and granulocyte-stimulating factors (*Sisti et al., 2016*).

Clobetasol propionate (CP), a highly potent drug of all the available corticosteroids is widely used in the treatment of various skin disorders including psoriasis, atopic dermatitis and vitiligo (*Patel et al., 2013*).

Microneedling is used as a method of transdermal drug delivery to increase the absorption of topical immunomodulator drugs. As, application of microneedling device to the skin can create transport pathways or micropores through the stratum

corneum. This technique is used to augment the absorption of drugs, enhance the efficacy, and decrease the period of therapy. In addition, microneedling keeps the epidermis partially intact, hastens recovery, and limits the risks of infection and scarring (*Mina et al., 2018*).